Aquilonius SM, Nyholm D. Development of new levodopa treatment strategies in Parkinson’s disease-from bedside to bench to bedside. Ups J Med Sci. 2017 Jun;122(2):71-77.


Bredenberg S., Nyholm D., Aquilonius S.M., Nyström C., 2003. An automatic dose dispenser for microtablets – A new concept for individual dosage of drugs in tablet form. Int. J. Pharm., 261, 137 – 146.


Patienters upplevelser och problem med tabletter som måste delas. Läkartidningen Nr 8, 2010, volym 107


Adler CH. Relevance of motor complications in Parkinson’s disease. Neurology 2002;58(4 Suppl 1):S51-56.


Goole J, Amighi K. Levodopa delivery systems for the treatment of Parkinson’s disease: an overview. Int J Pharm 2009;380(1-2):1-15.


Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson’s disease. Eur J Neurol 2006;13(11):1170-1185.


Jankovic J. Parkinson’s disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol 2000;23(5):252-261.


Johansson D, Ericsson A, Johansson A, Medvedev A, Nyholm D, Ohlsson F, Senek M, Spira J, Thomas I, Westin J, Bergquist F. Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry. CNS Neurosci Ther. 2018 May;24(5):439-447.


Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson’s disease. Mov Disord 2004;19(5):513-517.


LeWitt PA. Levodopa therapeutics for Parkinson’s disease: new developments. Parkinsonism Relat Disord 2009;15 Suppl 1:S31-34.


LeWitt PA. New levodopa therapeutic strategies. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S37-40.


Lökk J, Olofsson S, Persson U., 2014. Willingness to pay for a new drug delivery in Parkinson patients. J Multidiscip Healthc. Oct 1;7:431-40


Nyholm D, Lennernas H, Gomes-Trolin C, Aquilonius SM. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson’s disease on individual drug combinations. Clin Neuropharmacol 2002;25(2):89-96.


Nyholm D, Lewander T, Gomes-Trolin C, Bäckström T, Panagiotidis G, Ehrnebo M, Nyström C, Aquilonius SM. Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clin Neuropharmacol. 2012 May;35(3):111-7.


Nyholm D, Ehrnebo M, Lewander T, Trolin CG, Bäckström T, Panagiotidis G, Spira J, Nyström C, Aquilonius SM. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. Acta Neurol Scand. Article first published online: 4 JUL 2012


Poewe W, Antonini A. Novel formulations and modes of delivery of levodopa. Mov Disord. 2015 Jan;30(1):114-20


Senek M, Hellström M, Albo J, Svenningsson P, Nyholm D. First clinical experience with levodopa/carbidopa microtablets in Parkinson’s disease. Acta Neurol Scand. 2017 Dec;136(6):727-731.


Senek M, Aquilonius SM, Askmark H, Bergquist F, Constantinescu R, Ericsson A, Lycke S, Medvedev A, Memedi M, Ohlsson F, Spira J, Westin J, Nyholm D. Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment. Eur J Clin Pharmacol. 2017 May;73(5):563-571. doi: 10.1007/s00228-017-2196-4. Epub 2017 Jan 18.


Senek M, Nyholm D, Nielsen EI.. Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients. Eur J Clin Pharmacol. 2018 Jun 7.


Thomas I, Alam M, Bergquist F, Johansson D, Memedi M, Nyholm D, Westin J. Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson’s disease: a first experience. J Neurol. 2019 Jan 18. doi: 10.1007/s00415-019-09183-6